New Risk • Jul 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Large one-off items impacting financial results. Announcement • Jun 30
Frontier Biotechnologies Inc. to Report First Half, 2026 Results on Aug 31, 2026 Frontier Biotechnologies Inc. announced that they will report first half, 2026 results on Aug 31, 2026 Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.61 (vs CN¥0.12 loss in 1Q 2025) First quarter 2026 results: EPS: CN¥0.61 (up from CN¥0.12 loss in 1Q 2025). Revenue: CN¥297.1m (up CN¥268.8m from 1Q 2025). Net income: CN¥227.4m (up CN¥271.5m from 1Q 2025). Profit margin: 77% (up from net loss in 1Q 2025). Revenue is expected to decline by 32% p.a. on average during the next 2 years, while revenues in the Biotechs industry in China are expected to grow by 13%. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Apr 25
Frontier Biotechnologies Inc., Annual General Meeting, May 22, 2026 Frontier Biotechnologies Inc., Annual General Meeting, May 22, 2026, at 09:30 China Standard Time. Location: No. 9 Minzhi Road, Yuhuatai District, Nanjing, Jiangsu China Announcement • Mar 30
Frontier Biotechnologies Inc. to Report Q1, 2026 Results on Apr 30, 2026 Frontier Biotechnologies Inc. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 02
Full year 2025 earnings released: CN¥0.70 loss per share (vs CN¥0.54 loss in FY 2024) Full year 2025 results: CN¥0.70 loss per share (further deteriorated from CN¥0.54 loss in FY 2024). Revenue: CN¥143.7m (up 11% from FY 2024). Net loss: CN¥261.7m (loss widened 30% from FY 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Dec 26
Frontier Biotechnologies Inc. to Report Fiscal Year 2025 Results on Mar 31, 2026 Frontier Biotechnologies Inc. announced that they will report fiscal year 2025 results on Mar 31, 2026 New Risk • Nov 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 31
Third quarter 2025 earnings released: CN¥0.17 loss per share (vs CN¥0.089 loss in 3Q 2024) Third quarter 2025 results: CN¥0.17 loss per share (further deteriorated from CN¥0.089 loss in 3Q 2024). Revenue: CN¥44.7m (up 10% from 3Q 2024). Net loss: CN¥62.5m (loss widened 89% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Frontier Biotechnologies Inc. to Report Q3, 2025 Results on Oct 31, 2025 Frontier Biotechnologies Inc. announced that they will report Q3, 2025 results on Oct 31, 2025 New Risk • Jul 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.9% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change). Announcement • Jun 30
Frontier Biotechnologies Inc. to Report First Half, 2025 Results on Aug 30, 2025 Frontier Biotechnologies Inc. announced that they will report first half, 2025 results on Aug 30, 2025 Reported Earnings • May 03
First quarter 2025 earnings released: CN¥0.12 loss per share (vs CN¥0.15 loss in 1Q 2024) First quarter 2025 results: CN¥0.12 loss per share (improved from CN¥0.15 loss in 1Q 2024). Revenue: CN¥28.3m (up 15% from 1Q 2024). Net loss: CN¥44.1m (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Apr 30
Frontier Biotechnologies Inc., Annual General Meeting, May 23, 2025 Frontier Biotechnologies Inc., Annual General Meeting, May 23, 2025, at 09:30 China Standard Time. Location: Gate No. 5, Lize Road, Jiangning Development Zone, Nanjing, Jiangsu China Announcement • Mar 28
Frontier Biotechnologies Inc. to Report Q1, 2025 Results on Apr 30, 2025 Frontier Biotechnologies Inc. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Mar 02
Full year 2024 earnings released: CN¥0.54 loss per share (vs CN¥0.88 loss in FY 2023) Full year 2024 results: CN¥0.54 loss per share (improved from CN¥0.88 loss in FY 2023). Revenue: CN¥129.5m (up 13% from FY 2023). Net loss: CN¥201.5m (loss narrowed 39% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Board Change • Jan 26
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Guangji Wang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 27
Frontier Biotechnologies Inc. to Report Fiscal Year 2024 Results on Apr 30, 2025 Frontier Biotechnologies Inc. announced that they will report fiscal year 2024 results on Apr 30, 2025 New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Nov 28
Changdu Ruilekang Enterprise Management Co., Ltd completed the acquisition of 70% stake in Shanghai Frontier Jianling Biotechnology Co., Ltd. from Frontier Biotechnologies Inc. (SHSE:688221) Changdu Ruilekang Enterprise Management Co., Ltd agreed to acquire 70% stake in Shanghai Frontier Jianling Biotechnology Co., Ltd. from Frontier Biotechnologies Inc. (SHSE:688221) for CNY 141.26 million on August 26, 2024. Changdu Ruilekang Enterprise Management Co., Ltd will pay 77 million in common equity and pay CNY 64.26 million for the debt of Shanghai Frontier Jianling Biotechnology Co., Ltd. The transaction is subject to approval of offer by acquirer board. The deal has been approved by the board. Changdu Ruilekang Enterprise Management Co., Ltd reported total assets of CNY 429.27 million.
Changdu Ruilekang Enterprise Management Co., Ltd completed the acquisition of 70% stake in Shanghai Frontier Jianling Biotechnology Co., Ltd. from Frontier Biotechnologies Inc. (SHSE:688221) on November 27, 2024. Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023) Third quarter 2024 results: CN¥0.089 loss per share (improved from CN¥0.19 loss in 3Q 2023). Revenue: CN¥40.6m (up 36% from 3Q 2023). Net loss: CN¥33.0m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024 Frontier Biotechnologies Inc. announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 31
Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023) Second quarter 2024 results: CN¥0.28 loss per share (further deteriorated from CN¥0.26 loss in 2Q 2023). Revenue: CN¥26.4m (down 14% from 2Q 2023). Net loss: CN¥104.8m (loss widened 7.6% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Announcement • Jun 28
Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024 Frontier Biotechnologies Inc. announced that they will report first half, 2024 results on Aug 31, 2024 Reported Earnings • Mar 31
Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022) Full year 2023 results: CN¥0.88 loss per share (improved from CN¥0.98 loss in FY 2022). Revenue: CN¥114.2m (up 35% from FY 2022). Net loss: CN¥329.0m (loss narrowed 7.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Announcement • Mar 30
Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024 Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024, at 10:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Announcement • Mar 29
Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024 Frontier Biotechnologies Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 26
Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022) Full year 2023 results: CN¥0.88 loss per share (improved from CN¥0.98 loss in FY 2022). Revenue: CN¥114.2m (up 35% from FY 2022). Net loss: CN¥329.0m (loss narrowed 7.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Reported Earnings • Nov 02
Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022) Third quarter 2023 results: CN¥0.19 loss per share (improved from CN¥0.29 loss in 3Q 2022). Revenue: CN¥29.8m (down 5.4% from 3Q 2022). Net loss: CN¥69.4m (loss narrowed 33% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 30
Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022) Second quarter 2023 results: CN¥0.26 loss per share (further deteriorated from CN¥0.18 loss in 2Q 2022). Revenue: CN¥30.5m (up 49% from 2Q 2022). Net loss: CN¥97.4m (loss widened 52% from 2Q 2022). Announcement • Jun 28
Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023 Frontier Biotechnologies Inc. announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • May 02
First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022) First quarter 2023 results: CN¥0.20 loss per share (further deteriorated from CN¥0.16 loss in 1Q 2022). Revenue: CN¥11.9m (up 110% from 1Q 2022). Net loss: CN¥75.7m (loss widened 28% from 1Q 2022). Revenue is forecast to grow 97% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Reported Earnings • Oct 26
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: CN¥0.29 loss per share (further deteriorated from CN¥0.23 loss in 3Q 2021). Net loss: CN¥103.3m (loss widened 23% from 3Q 2021). Revenue missed analyst estimates by 60%. Earnings per share (EPS) exceeded analyst estimates by 34%. Revenue is forecast to grow 80% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Reported Earnings • Sep 02
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: CN¥0.18 loss per share (down from CN¥0.14 loss in 2Q 2021). Net loss: CN¥64.0m (loss widened 32% from 2Q 2021). Revenue missed analyst estimates by 69%. Earnings per share (EPS) exceeded analyst estimates by 52%. Over the next year, revenue is forecast to grow 753%, compared to a 37% growth forecast for the Biotechs industry in China. Announcement • Aug 09
Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID Frontier Biotechnologies, a biopharmaceutical company focused on the discovery, development and dissemination of innovative medicines that improve patient health, announced positive results from the Phase 1 clinical trial of its drug candidate, FB2001 – a small molecule inhibitor of coronavirus main protease (Mpro) – in healthy adult volunteers. The data, presented at the poster session of the 11thInternational Conference on Emerging Infectious Diseases (ICEID), showed FB2001 to be safe and well tolerated among trial participants. Adverse events reported during the trial were mostly mild-to-moderate in severity, with no significant differences observed between participants in the Chinese and American study centers. A total of 120 participants (80 Whites in the US and 40 Chinese in China) received intravenous infusions of FB2001 at either single doses from 5 mg to 400 mg, or multiple doses of 30 mg to 400 mg daily for 5 days. The key findings from the study are as follows: FB2001 was safe and well tolerated up to 400 mg per day Without using a pharmacokinetic enhancer, FB2001 exhibited plasma and lung drug concentration above the in vitro antiviral EC50 value. No significant difference was observed between Chinese and American populations. The results from the Phase 1 trial build on preclinical in vivo data of FB2001, where the drug was observed to reduce viral loads in both the lung and brain tissues of mice. Pharmacokinetic data obtained from preclinical studies showed significantly higher concentration of FB2001 in the lung compared to plasma. Announcement • Jul 22
Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited Frontier Biotechnologies Inc. announced a private placement issue not more than 20,000,000 A shares for an aggregate proceeds of CNY 270,200,000 on July 21, 2022. The transaction also included participation from Jiezheng Investment Group Co., Ltd, Nuode Fund Management Co., Ltd., Xie Hui, Qingdao Jiezheng Haicheng Trading Co., Ltd., UBS AG, Centennial Insurance Asset Management Co., Ltd. - Centennial Life Insurance Co., Ltd. - Participating Insurance Products, and Guodu Venture Capital Co., Ltd.-Guodu Benfu No. 3 Private Equity Investment Fund. The transaction has been approved by the Second Meeting of the Third Board of Directors. Reported Earnings • May 02
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: CN¥0.16 loss per share (down from CN¥0.12 loss in 1Q 2021). Net loss: CN¥59.2m (loss widened 32% from 1Q 2021). Revenue missed analyst estimates by 51%. Earnings per share (EPS) exceeded analyst estimates by 15%. Over the next year, revenue is forecast to grow 2,386%, compared to a 45% growth forecast for the industry in China. Price Target Changed • Apr 27
Price target increased to CN¥22.90 Up from CN¥20.80, the current price target is provided by 1 analyst. New target price is 61% above last closing price of CN¥14.25. Stock is down 7.5% over the past year. The company is forecast to post a net loss per share of CN¥0.73 next year compared to a net loss per share of CN¥0.74 last year. Reported Earnings • Feb 28
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: CN¥0.74 loss per share (up from CN¥0.80 loss in FY 2020). Net loss: CN¥266.0m (loss widened 15% from FY 2020). Revenue missed analyst estimates by 51%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 2,374%, compared to a 37% growth forecast for the pharmaceuticals industry in China. Reported Earnings • Oct 16
Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020) Third quarter 2021 results: Net loss: CN¥83.9m (loss widened 36% from 3Q 2020). Reported Earnings • Aug 18
Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020) Second quarter 2021 results: Net loss: CN¥48.6m (loss narrowed 21% from 2Q 2020). Announcement • Jul 20
Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients Frontier Biotechnologies announced positive top-line results for its phase 3 TALENT study, which demonstrated that an ABT-based two-drug treatment arm was non-inferior to a lopinavir (LPV)-based three-drug arm (75.7% vs 77.3%). The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks. The drug demonstrated efficacy against major strains of HIV, including resistant strains. Additionally, the subjects who experienced virological failure at 48 weeks did not present with treatment emergent resistant associated mutations with gp41. The high genetic barrier to resistance of ABT+LPV/r meant no further resistance developed against these agents, which is important to avoid compromising future drug options for these treatment-experienced HIV patients. Reported Earnings • Apr 01
Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019) Full year 2020 results: Net loss: CN¥230.7m (loss widened 20% from FY 2019). Is New 90 Day High Low • Jan 29
New 90-day low: CN¥16.16 The company is down 36% from its price of CN¥25.17 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. 
